Skip to main content
NCBI home page
Cytotechnology logoLink to Cytotechnology
. 1998 Sep;27(1-3):237–247. doi: 10.1023/A:1008081208312

The extended-MDR phenotype

Ross Davey 1, Mary Davey 2
PMCID: PMC3449556  PMID: 19002795

Abstract

Cellular models have made a significant contribution to our understanding of the molecular mechanisms of resistance to chemotherapeutic drugs. However the vast majority of these models involve cell sublines with high levels of resistance generated by continuous exposure to high drug doses, and although the majority express a multidrug resistance (MDR) phenotype, they fall short of the broader drug cross resistance that is characteristic of cancers which no longer respond to treatment. Several studies have reported cell sublines which not only have the MDR phenotype and are resistant to ‘natural product’ lipophilic drugs, but they are also resistant to alkylating agents and antimetabolites. A common feature of these sublines is they were generated by treatment with low, clinically relevant levels of drug given intermittently. The term extended-MDR has been used to describe this type of broad drug cross resistance. Here we review those factors that promote the development of extended-MDR, the characteristics of extended-MDR sublines and the possible resistance mechanisms involved.

Keywords: extended-MDR, glutathione, MRP, P-glycoprotein

Full Text

The Full Text of this article is available as a PDF (170.5 KB).

Contributor Information

Ross Davey, Email: rdavey@med.usyd.edu.au.

Mary Davey, Email: Mary.Davey@uts.edu.au.

References

  1. Barnouin K, Leier I, Jedlitschky G, PourtierManzanedo A, Konig J, Lehmann WD, Keppler D. Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Brit J Cancer. 1997;77:201–209. doi: 10.1038/bjc.1998.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Batist G, Torres-Garcia S, Demuys J, Greene D, Lehnert S, Rochon MandPanasci L. Enhanced DNA cross-link removal: The apparent mechanism of resistance in a clinically relevant melphalan resistant human breast cancer cell line. Mol Pharmacol. 1989;36:224–230. [PubMed] [Google Scholar]
  3. Bielack SS, Kallenbach K, Looft G, Erttmann R, Winkler K. Structurally modified anthracyclines retain activity in a cell line with simultaneous typical and atypical multidrug resistance. Anticancer Res. 1995;15:1279–1284. [PubMed] [Google Scholar]
  4. Boege F. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects. Eur J Clin Chem Clin Biochem. 1996;34:873–888. [PubMed] [Google Scholar]
  5. Chao CC (1995) Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression. [DOI] [PubMed]
  6. Chao CCK. Cross-resistance to cis-diamminedi-chloroplatinum (ii) of a multidrug-resistant lymphoma cell line associated with decreased drug accumulation and enhanced DNA repair. Eur J Pharmacol. 1996;305:213–222. doi: 10.1016/0014-2999(96)00168-9. [DOI] [PubMed] [Google Scholar]
  7. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650–1654. doi: 10.1126/science.1360704. [DOI] [PubMed] [Google Scholar]
  8. Davey RA, Su GM, Hargrave RM, Harvie RM, Baguley BC, Davey MW. The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro. Cancer Chemother Pharmacol. 1997;39:424–430. doi: 10.1007/s002800050593. [DOI] [PubMed] [Google Scholar]
  9. Davey R, Longhurst T, Davey M, Belov L, Harvie R, Hancox D, Wheeler H. Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leuk Res. 1995;19:275–282. doi: 10.1016/0145-2126(94)00159-8. [DOI] [PubMed] [Google Scholar]
  10. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137–171. doi: 10.1146/annurev.bi.58.070189.001033. [DOI] [PubMed] [Google Scholar]
  11. Gazdar A, Carney D, Russell E, Sims H, Baylin S, Bunn P. G., Jr, Minna J. Establishment of continuous, clonable cultures of small-cell carcinoma of the lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res. 1980;40:3502–3507. [PubMed] [Google Scholar]
  12. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet. 1995;29:607–649. doi: 10.1146/annurev.ge.29.120195.003135. [DOI] [PubMed] [Google Scholar]
  13. Hamaguchi K, Godwin AK, Yakushiji M, O'Dwyer PJ. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 1993;53:5225–5232. [PubMed] [Google Scholar]
  14. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997;89:1845–1853. [PubMed] [Google Scholar]
  15. Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD, Kuo MT. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem. 1996;271:14981–14988. doi: 10.1074/jbc.271.7.3633. [DOI] [PubMed] [Google Scholar]
  16. Kavallaris M. The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance. Anti-Cancer Drugs. 1997;8:17–25. doi: 10.1097/00001813-199701000-00002. [DOI] [PubMed] [Google Scholar]
  17. Kellen JA. Molecular interrelationships in multidrug resistance. Anticancer Res. 1994;14:433–435. [PubMed] [Google Scholar]
  18. Keppler D, Konig J. Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB. 1997;11:509–516. doi: 10.1096/fasebj.11.7.9212074. [DOI] [PubMed] [Google Scholar]
  19. Kool M, DeHaas M, Scheffer GL, Scheper RJ, Van Eijk MJT, Juijn JA, Baas F, Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997;57:3537–3543. [PubMed] [Google Scholar]
  20. List AF, Spier CM, Cline A, Doll DC, Garewal H, Morgan R, Sandberg AA. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Brit J Haematol. 1991;78:28–34. doi: 10.1111/j.1365-2141.1991.tb04378.x. [DOI] [PubMed] [Google Scholar]
  21. Little C, Nau M, Carney D, Gazdar A, Minna J. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature. 1983;306:194–196. doi: 10.1038/306194a0. [DOI] [PubMed] [Google Scholar]
  22. Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer. 1996;32A:945–957. doi: 10.1016/0959-8049(96)00046-9. [DOI] [PubMed] [Google Scholar]
  23. Marks DC, Belov L, Davey MW, Davey RA, Kidman AD. The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leukemia Res. 1992;16:1165–1173. doi: 10.1016/0145-2126(92)90114-M. [DOI] [PubMed] [Google Scholar]
  24. Marks DC, Davey MW, Davey RA, Kidman AD. Differentiation and multidrug resistance in response to drug treatment in the K562 human leukaemia cell line. Brit J Haematol. 1993;84:83–89. doi: 10.1111/j.1365-2141.1993.tb03028.x. [DOI] [PubMed] [Google Scholar]
  25. Marks DC, Su GMI, Davey RA, Davey MW. Extended multidrug resistance in haemopoietic cells. Brit J Haematol. 1996;95:587–595. doi: 10.1046/j.1365-2141.1996.d01-1951.x. [DOI] [PubMed] [Google Scholar]
  26. Masanek U, Stammler G, Volm M. Messenger RNA expression of resistance proteins and related factors in human ovarian carcinoma cell lines resistant to doxorubicin, taxol and cisplatin. Anti-Cancer Drugs. 1997;8:189–198. doi: 10.1097/00001813-199702000-00010. [DOI] [PubMed] [Google Scholar]
  27. Mattern J, Volm M. Resistance mechanisms in human lung cancer. Invasion and Metastasis. 1995;15:81–94. [PubMed] [Google Scholar]
  28. Mellish KJ, Barnard CF, Kelland LR, Harrap KR. Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)] Int J Cancer. 1994;59:65–70. doi: 10.1002/ijc.2910590114. [DOI] [PubMed] [Google Scholar]
  29. O'Brien ML and Tew KD (1996) Glutathione and related enzymes in multidrug resistance. Eur J Cancer 32A: 967-978. [DOI] [PubMed]
  30. Roy SN, Horwitz SB. A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res. 1985;45:3856–3863. [PubMed] [Google Scholar]
  31. Shen HX, Paul S, Breuninger LM, Ciaccio PJ, Laing NM, Helt M, Tew KD, Kruh GD. Cellular and in vitro transport of glutathione conjugates by MRP. Biochemistry. 1996;35:5719–5725. doi: 10.1021/bi960098n. [DOI] [PubMed] [Google Scholar]
  32. Su GM, Davey MW, Davey RA, Kidman AD. Development of extended multidrug resistance in HL60 promyelocytic leukaemia cells. Brit J Haematol. 1994;88:566–574. doi: 10.1111/j.1365-2141.1994.tb05075.x. [DOI] [PubMed] [Google Scholar]
  33. Su GM, Davey MW, Davey RA. Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. Int J Cancer. 1998;76:702–708. doi: 10.1002/(SICI)1097-0215(19980529)76:5<702::AID-IJC15>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  34. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S, Kuwano M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996;56:4124–4129. [PubMed] [Google Scholar]
  35. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994;54:4313–4320. [PubMed] [Google Scholar]
  36. Tjuljandin SA, Doig RG, Sobol MM, Watson DM, Sheridan WP, Morstyn G, Mihaly G, Green MD. Pharmacokinetics and toxicity of two schedules of high dose epirubicin. Cancer Res. 1990;50:5095–5101. [PubMed] [Google Scholar]
  37. Yang LY, Trujillo JM, Siciliano MJ, Kido Y, Siddik ZH, Su YZ. Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II) Int J Cancer. 1993;53:478–485. doi: 10.1002/ijc.2910530321. [DOI] [PubMed] [Google Scholar]
  38. Yang XW, Page M. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol Res. 1995;7:619–624. [PubMed] [Google Scholar]

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES